Carmen Silvia Gabetta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmen Silvia Gabetta has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
1 shared publication - Alulin Tácio Quadros Santos Monteiro Fonseca
Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
1 shared publication - Athene Maria de Marco França Mauro
Secretaria Municipal da Saúde de São Paulo, São Paulo 01509-020, Brazil
1 shared publication - Bruna Glaucia Farah
Newborn Screening Reference Service, Instituto Jô Clemente (IJC), São Paulo 04040-033, Brazil
1 shared publication - Carlos Eugenio Fernandez de Andrade
Secretaria Municipal da Saúde de São Paulo, São Paulo 01509-020, Brazil
1 shared publication - Carmela Maggiuzzo Grindler
Secretaria de Estado da Saúde de São Paulo, São Paulo 01027-000, Brazil
1 shared publication
Latest Publications
- Open Access
- 7 July 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (3) , 50
Expanding 5q-SMA Newborn Screening in Latin America: A Brazilian Model for National and Regional Implementation
5q spinal muscular atrophy (5q-SMA) is a leading genetic cause of infant mortality. Presymptomatic intervention with disease-modifying therapies significantly improves motor outcomes, but effectiveness depends on early detection through newborn screening (NBS). Despite global 5q-SMA NBS expansion and recent Brazilian federal legislation, regional disparities and a lack of systematic monitoring hinder access to timely diagnosis and care. This study addresses these gaps by evaluating a statewide pilot program in São Paulo. We used multiplex real-time PCR to detect SMN1 exon 7 deletions in dried blood spots, confirming SMN1/2 copy numbers via MLPA in positive cases. Under real-world conditions, timeliness key performance indicators were evaluated to assess operational efficiency. 194,714 newborns were screened with 14 positive cases, yielding a prevalence of 1:13,908. First-tier results and treatment initiation occurred at a median of 10.8 and 28 days of life, respectively. Notably, 78.6% of patients had two SMN2 copies, of which approximately half were symptomatic by the first evaluation, highlighting the critical need for rapid screening to prevent irreversible motor decline. Screening achieved 100% specificity. This pilot demonstrates the feasibility of 5q-SMA NBS within the Brazilian public health system, providing essential evidence to overcome logistical and socioeconomic barriers and support nationwide expansion.
- 7 July 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (3) , 50
Open AccessExpanding 5q-SMA Newborn Screening in Latin America: A Brazilian Model for National and Regional Implementation
5q spinal muscular atrophy (5q-SMA) is a leading genetic cause of infant mortality. Presymptomatic intervention with disease-modifying therapies significantly improves motor outcomes, but effectiveness depends on early detection through newborn screening (NBS). Despite global 5q-SMA NBS expansion and recent Brazilian federal legislation, regional disparities and a lack of systematic monitoring hinder access to timely diagnosis and care. This study addresses these gaps by evaluating a statewide pilot program in São Paulo. We used multiplex real-time PCR to detect SMN1 exon 7 deletions in dried blood spots, confirming SMN1/2 copy numbers via MLPA in positive cases. Under real-world conditions, timeliness key performance indicators were evaluated to assess operational efficiency. 194,714 newborns were screened with 14 positive cases, yielding a prevalence of 1:13,908. First-tier results and treatment initiation occurred at a median of 10.8 and 28 days of life, respectively. Notably, 78.6% of patients had two SMN2 copies, of which approximately half were symptomatic by the first evaluation, highlighting the critical need for rapid screening to prevent irreversible motor decline. Screening achieved 100% specificity. This pilot demonstrates the feasibility of 5q-SMA NBS within the Brazilian public health system, providing essential evidence to overcome logistical and socioeconomic barriers and support nationwide expansion.